P164 - Establishing a resource for comprehensive molecular subtyping of bladder cancer

Publication date: November 2018Source: European Urology Supplements, Volume 17, Issue 14Author(s): C. Fragkoulis, K. Stasinopoulos, I. Glykas, R. Stroggilos, A. Vlahou, G. Papadopoulos, G. Stathouros, J. Zoidakis, K. Ntoumas
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research

Related Links:

Authors: Vantaku V, Donepudi SR, Ambati CR, Jin F, Putluri V, Nguyen K, Rajapakshe K, Coarfa C, Battula VL, Lotan Y, Putluri N Abstract [This corrects the article DOI: 10.18632/oncotarget.21038.]. PMID: 31827727 [PubMed - in process]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
             Basel, 13 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS). The study showed adding Tecentriq ® (atezolizumab) to Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) helped to reduce the risk of disease worsening or death, compared to placebo plus Cotellic and Zelboraf. A significant and clinically meaningful improvement in PFS was demonstrated in the study. The safety ...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
(Medical College of Georgia at Augusta University) While trying to develop a comparatively easy, inexpensive way to give physicians and their patients with bladder cancer a better idea of likely outcome and best treatment options, scientists found that sophisticated new subtyping techniques designed to do this provide no better information than long-standing pathology tests.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
In this study we were aiming to identify potent GLO-I inhibitors as potential candidates for the development of effective anticancer therapeutics using an integrated ligand- and structure-based drug design approach. A set of selective pharmacophore models was generated using an in-house tested set of flavonoids and used in virtual screening of Maybridge and Aldrich databases, collectively containing more than 64,000 compounds. Filtration of retained hits resulted in 362 compounds that were docked into the active site of the GLO-I enzyme. Then, the top 30% of docked compounds were visually inspected and 32 compounds were pu...
Source: Medicinal Chemistry Research - Category: Chemistry Source Type: research
Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Source Type: research
Publication date: Available online 11 December 2019Source: Best Practice &Research Clinical Endocrinology &MetabolismAuthor(s): Giusy Elia, Silvia Martina Ferrari, Maria Rosaria Galdiero, Francesca Ragusa, Sabrina Rosaria Paparo, Ilaria Ruffilli, Gilda Varricchi, Poupak Fallahi, Alessandro AntonelliAbstractAnticancer immunotherapy, in the form of immune checkpoint inhibition (ICI), is a paradigm shift that has transformed the care of patients with different types of solid and hematologic cancers. The most notable improvements have been seen in patients with melanoma, non-small-cell lung, bladder, renal, cervical, u...
Source: Best Practice and Research Clinical Endocrinology and Metabolism - Category: Endocrinology Source Type: research
CONCLUSION: Unlike unadjusted SMI, sarcopenia was not associated with survival or complications. LEVEL OF EVIDENCE: 3. PMID: 31818689 [PubMed - as supplied by publisher]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
Analyst, 2019, Accepted Manuscript DOI: 10.1039/C9AN01911A, PaperFabian Placzek, Eliana Cordero, Simon Michael Kretschmer, Lara Wurster, Florian Knorr, Gerardo Gonzales-Cerdas, Mikael T. Erkkilae, Patrick Stein, Caglar Ataman, Gregers Hermann, Karin Mogensen, Thomas Hasselager, Peter E. Andersen, Hans Zappe, J ürgen Popp, Wolfgang Drexler, Rainer Leitgeb, Iwan W. Schie Non-muscle-invasive bladder cancer affects millions of people worldwide, resulting in significant discomfort to the patient and potential death. Today, cystoscopy is the gold standard for bladder cancer assessment, using white... The content of this RSS...
Source: RSC - Analyst latest articles - Category: Chemistry Authors: Source Type: research
Condition:   Bladder Cancer Intervention:   Diagnostic Test: immediate urine cytology Sponsor:   Mansoura University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
PROSTATE cancer is the most common cancer in men in the UK and treatment outcomes depend greatly on how early it is caught. The warning signs associated with the disease are associated with the bladder and men who experience a certain issue in cold weather should not rule out the disease.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Urology & Nephrology